I am very encouraged by the progress and achievements announced by Resverlogix so far this year. They have clearly been working hard to advance and launch of the renal trial, and will have ample presentation opportunities at ERA-EDTA to highlight the imminent launch of this trial. The Fabry's Disease trial is also in the works. Resverlogix has been very active at presenting at various scientific conferences. They just published the recent apabetalone/complement cascade paper and have also been a part of some 3rd party research/publications. The date of the BETonMACE futility analysis and 4th DSMB report are out of the control of Resverlogix. They will happen when they happen and hopefully will be good news.

This is all very good progress and indicative of a well-organized, competent and successful team at Resverlogix. Of course, we are all anxious to hear some news and get some clarity on the issue of Loan/Financing. In addition to the achievements/announcements above, Resverlogix indicated at their October 2016 R&D presentation and their December 2016 Annual meeting of several other goals including:

• Licensing/Partnering Deal announcement
• New Analysts
• New website in the next quarter (per communication with Sarah)
• FDA Interactions and US involvement in BETonMACE
• Update on BETonMACE enrollment and Taiwan/China and Russia involvement
• Paroxysmal nocturnal hemoglobinuria (PNH) Orphan Trial
• Plans for the confirmed second clinical compound IND candidate that was announced at October 201 R&D meeting
• Plans for seven compounds chosen for follow-on testing inlcuding RVX-206, RVX-641, RVX-2101, RVX-2113 (one of these may be the second clinical compound IND candidate above.

Hopefully, we will get more updates on these above items soon. Based on the flow of information so far in 2017, I am encouraged that Resverlogix will continue to keep us shareholders informed on these above issues as they are able. I am hoping we get a corporate update webcast in a couple of weeks at BIO International where Resverlogix presents on June 19th. This would be an excellent opportunity to update us on some of these items.

Best regards,

BearDownAZ